Effects of folate supplementation on two provisional molecular markers of colon cancer: A prospective, randomized trial

Citation
Yi. Kim et al., Effects of folate supplementation on two provisional molecular markers of colon cancer: A prospective, randomized trial, AM J GASTRO, 96(1), 2001, pp. 184-195
Citations number
72
Categorie Soggetti
Gastroenerology and Hepatology
Journal title
AMERICAN JOURNAL OF GASTROENTEROLOGY
ISSN journal
00029270 → ACNP
Volume
96
Issue
1
Year of publication
2001
Pages
184 - 195
Database
ISI
SICI code
0002-9270(200101)96:1<184:EOFSOT>2.0.ZU;2-C
Abstract
OBJECTIVES: Dietary folate intake is inversely associated with the risk of colorectal cancer. This study investigated the effect of folate supplementa tion on genomic DNA methylation and DNA strand breaks in exons 5-8 of the p 53 gene of the colonic mucosa, two provisional biomarkers of colon cancer. METHODS: Twenty subjects with adenomas were randomized to receive either fo late (5 mg/day) or placebo for 1 yr after polypectomy. At baseline, 6 month s and 1 yr, systemic and colonic measures of folate status were determined, as were the biomarkers mentioned earlier. RESULTS: Folate supplementation increased serum, red blood cell and colonic mucosal folate concentrations (p < 0.02). Folate supplementation also incr eased the extent of genomic DNA methylation at 6 months and 1 yr (p = 0.001 ), whereas placebo administration was associated with an increase in the ex tent of genomic DNA methylation only at 1 yr. Similarly, folate supplementa tion decreased the extent of p53 strand breaks in exons 5-8 at 6 months and 1 yr (p < 0.02), whereas placebo administration was associated with a decr ease in the extent of p53 strand breaks only at 1 yr. CONCLUSIONS: Both of these provisional biomarkers of colon cancer underwent accelerated improvement at 6 months with folate supplementation. However, these markers also improved with placebo at 1 yr. Therefore, potential conf ounding factors that seem to modulate these biomarkers need to be identifie d and corrected in order for these markers to serve as suitable surrogate e ndpoints in folate chemoprevention trials. (Am J Gastroenterol 2001;96:184- 195. (C) 2001 by Am. Coll. of Gastroenterology).